Application of hsacirc0045128 in predicting prognosis condition of AIS-LVO intravascular treatment

By detecting the expression level of hsa_circ_0045128, a biomarker is provided for predicting the prognosis of endovascular treatment of AIS-LVO, which solves the problem of early prediction of prognosis in patients with acute large vascular occlusion stroke, and realizes the prognosis of endovascular treatment Efficiently distinguished, with high sensitivity and specificity.

CN119040452APending Publication Date: 2024-11-29THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411297300.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-18
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Patients with acute large vascular occlusion stroke (AIS-LVO) lack effective detection methods to predict the prognosis of intravascular treatment in the early stage, which leads to difficulty in predicting prognosis and affects the treatment effect.

Method used

Using hsa_circ_0045128 as a biomarker, by detecting its expression level, it provides a detection reagent that predicts the prognosis of AIS-LVO intravascular therapy, including plasma collection, RNA extraction, reverse transcription and real-time fluorescence quantitative PCR detection, and combines statistical analysis to determine the prognosis. .

Benefits of technology

hsa_circ_0045128 has high predictive value. ROC curve analysis shows that it can better distinguish patients with good and poor endovascular treatment prognosis, with 82.14% sensitivity and 76.92% specificity, as an important indicator for early prediction of adverse prognosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040452A_ABST
    Figure CN119040452A_ABST
Patent Text Reader

Abstract

The invention provides an application of hsacirc0045128 serving as a molecular biomarker in preparation of a detection reagent for predicting AIS-LVO intravascular treatment prognosis conditions, and a nucleotide sequence of the hsacirc0045128 is shown as SEQ ID NO. 1. The invention also provides an application of the hsacirc0045128 in preparation of a detection reagent for predicting AIS-LVO intravascular treatment prognosis conditions. Results based on ROC curve analysis show that the hsacirc0045128 can effectively distinguish patients with poor prognosis and good prognosis after treatment, the area under the curve is 0.845, and the hsacirc0045128 has the sensitivity of 82.14% and the specificity of 76.92%. The invention provides a brand new retrieval means which can be used for early prediction of the prognosis condition of the AIS-LVO patient after the AIS-LVO patient receives intravascular treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine and molecular biology, and specifically relates to the application of hsa_circ_0045128 as a marker for diagnosing the prognosis of intravascular treatment of AIS-LVO. Background Art

[0002] Acute ischemic stroke with large vessel occlusion (AIS-LVO) accounts for 30-40% of all ischemic stroke types, with a 90-day mortality rate of 60% and a 6-month mortality rate of 90%, indicating an extremely poor prognosis. Since 2015, several large clinical randomized controlled studies have shown that endovascular therapy (EVT) based on neurointerventional technology can significantly improve the clinical prognosis of patients with ischemic stroke caused by large vessel occlusion, and has become the first-line treatment for AIS-LVO. Although the target vessel patency rate after endovascular treatment is as high as 80-90%, successful vascular recanalization is not always associated with a good functional prognosis. About 50% of patients cannot achieve a good functional prognosis 90 days after endovascular treatment. Actively exploring predictive indicators for poor prognosis of endovascular treatment will help reduce the morbidity and mortality of ischemic stroke. At present, there is a lack of early detection methods for predicting the prognosis of endovascular treatment for AIS-LVO. Summary of the invention

[0003] In view of the fact that there is currently a lack of means for early prediction of the prognosis of intravascular treatment of AIS-LVO, the present invention proposes a corresponding prediction method and reagent, and prepares a detection reagent by using hsa_circ_0045128 as a biomarker for early prediction of the prognosis of intravascular treatment of AIS-LVO to solve the problems raised in the above background technology.

[0004] To achieve the above objectives, the present invention provides the following technical solution: a molecular biomarker for predicting the prognosis of AIS-LVO intravascular treatment, wherein the molecular biomarker is hsa_circ_0045128, and its nucleotide sequence is shown in SEQ ID NO.1.

[0005] As a second aspect, the present invention also provides the use of hsa_circ_0045128 as a marker in the preparation of a detection reagent for predicting the prognosis of intravascular treatment of AIS-LVO.

[0006] As a third aspect, the present invention also provides a detection reagent for predicting the prognosis of AIS-LVO intravascular treatment, which includes a reagent for detecting hsa_circ_0045128; the reagent for detecting hsa_circ_0045128 includes primers shown in SEQ ID NO.2 and SEQ ID NO.3, and primers of internal reference genes.

[0007] Preferably, the internal reference gene is GAPDH, and the primer sequences of the internal reference gene are shown in SEQ NO:4 and SEQ NO:5;

[0008] As a fourth aspect, the present invention also provides a detection kit for predicting the prognosis of intravascular treatment of AIS-LVO, which includes the above-mentioned detection reagent. The method of using the detection kit includes:

[0009] S1: plasma collection and processing;

[0010] S2: RNA extraction and reverse transcription;

[0011] S3: Real-time fluorescence quantitative PCR detection of the expression level of hsa_circ_0045128;

[0012] S4: Statistical analysis was used to determine the prognosis of endovascular treatment of AIS-LVO.

[0013] Compared with the prior art, the technical effects of the present invention are:

[0014] (1) The new molecular marker hsa_circ_0045128 for detecting the prognosis of intravascular treatment in patients with AIS-LVO of the present invention provides a new means for early prediction of the prognosis of intravascular treatment in patients with AIS-LVO;

[0015] (2) The marker hsa_circ_0045128 of the present invention has a high predictive value. ROC curve analysis shows that it can better distinguish AIS-LVO patients with poor prognosis after endovascular treatment from AIS-LVO patients with good prognosis after endovascular treatment. The area under the curve is 0.848, with a sensitivity of 82.14% and a specificity of 76.92%. It can be used as an important indicator for early prediction of poor prognosis of endovascular treatment in AIS-LVO patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 Annotate the function of hsa_circ_0045128 in parental genes;

[0017] Figure 2is the relative expression level of hsa_circ_0045128 in the plasma of AIS-LVO patients with poor prognosis after endovascular treatment and AIS-LVO patients with good prognosis after endovascular treatment;

[0018] Figure 3 This is the ROC curve of hsa_circ_0045128 for early prediction of poor prognosis of endovascular treatment in patients with AIS-LVO. DETAILED DESCRIPTION

[0019] In order to make the purpose, technical scheme and effect of the present invention clearer and more specific, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0020] Example

[0021] The inventors screened out highly expressed circRNA molecules with good differences in the plasma of ischemic stroke patients through early bioinformatics analysis and clinical trials for screening and verification analysis. The present invention selected hsa_circ_0045128 (SEQ ID NO.1) and used it for early prediction of poor prognosis of intravascular treatment in AIS-LVO patients through subsequent verification and combined with statistical analysis.

[0022] (1) Research subjects and samples

[0023] A total of 80 patients with AIS-LVO and endovascular treatment admitted to the Affiliated Hospital of Xuzhou Medical University from February 2023 to April 2023 were selected (all patients signed informed consent forms and were approved by the Ethics Committee of Xuzhou Medical University). Among them, 52 patients had a good prognosis and 28 patients had a poor prognosis. 5 ml of human peripheral blood was obtained using a vacuum blood collection tube (EDTA-K2 anticoagulant tube) and placed at room temperature for 30-45 minutes. Centrifuge at 2500 rpm for 25 minutes at 4°C to obtain the upper plasma sample, and the plasma was dispensed into nuclease-free centrifuge tubes and stored at -80°C.

[0024] (2) RNA extraction

[0025] 200 μL of plasma sample was mixed with 1 mL of Trizol LS lysis reagent and allowed to stand at room temperature (15-25°C) for 5 min;

[0026] Add 200 μL of chloroform to the mixture, shake vigorously for 15 seconds, and then let it stand at room temperature for 3 minutes;

[0027] The sample was centrifuged at 4°C and 12,000 g for 15 min, and the upper colorless aqueous phase was aspirated into a 1.5 mL nuclease-free centrifuge tube;

[0028] Add 500 μL of isopropanol to the obtained colorless aqueous solution, mix by inverting, and let stand at room temperature for 10 minutes;

[0029] Centrifuge again at 4°C, 12000 g for 10 min, remove the supernatant, and leave the RNA gel;

[0030] Add 1 mL of 75% ethanol to wash the RNA precipitate, mix by inverting, centrifuge at 12000 g for 5 minutes at 4°C, discard the supernatant, leave to dry at room temperature for 10 minutes, add 10-20 μL of DEPC water, incubate at 55-60°C for 10 minutes, and place on ice;

[0031] Take 1 μL of sample, determine the purity and concentration using a spectrophotometer, and store the sample at -80°C.

[0032] (3) cDNA synthesis

[0033] According to the recipe in Table 1, a reaction mixture for removing genomic DNA (Vazyme) was prepared on ice, and then 1 μg of RNA was pipetted into the reaction mixture and incubated at 42° C. for 2 minutes.

[0034] Table 1 Reaction mixture for removing genomic DNA

[0035]

[0036] According to the ingredients in Table 2, prepare the reverse transcription reaction mixture (Vazyme) on ice, mix well and run in a PCR instrument according to the following program: incubate at 50°C for 15 minutes, then keep at 85°C for 2 minutes. The obtained products can be directly analyzed by qPCR or stored in a -20°C refrigerator.

[0037] Table 2 Reverse transcription reaction system

[0038]

[0039] (4) Real-time PCR

[0040] According to the formula in Table 3, the fluorescence quantitative PCR reaction mixture was prepared under low temperature conditions. After mixing evenly, the PCR plate was placed on the CFX96 fluorescence quantitative PCR instrument for PCR reaction, and the operation was performed according to the procedure shown in Table 4.

[0041] Table 3 Fluorescence quantitative PCR reaction system

[0042]

[0043] Table 4 Fluorescence quantitative PCR reaction procedure

[0044]

[0045] Each sample was subjected to three replicate experiments, and its Ct value was recorded. Samples with Ct values ​​greater than 35 were excluded. Using 3-phosphoglyceraldehyde dehydrogenase (GAPDH) as an internal reference, the difference between the Ct value of each candidate circRNA and the Ct value of GAPDH was calculated to obtain the ΔCt value. The ΔCt value of the experimental group was subtracted from the ΔCt value of the control group to obtain the ΔΔCt value. The relative expression of circRNA was calculated as follows: -ΔΔCt .

[0046] Specific primers for PCR:

[0047] Forward primer (SEQ ID NO. 2): 5'-GCTTTTCAGAATCTTATCAACGACG-3'

[0048] Reverse primer (SEQ ID NO. 3): 5'-CATGAGGGTTGGCAGAGCAG-3'

[0049] The internal reference gene is GAPDH-specific PCR primer:

[0050] Forward primer (SEQ ID NO.4): 5'-GAACGGGAAGCTCACTGG-3'

[0051] Reverse primer (SEQ ID NO.5): 5'-GCCTGCTTCACCACCTTCT-3'

[0052] (5) Statistics and results analysis

[0053] The present invention uses SPSS26.0 and GraphPad Prism 9 software for statistical analysis. The differences between the two groups were compared using independent sample t-test. Receiver operating characteristic curve (ROC) analysis was used to evaluate the diagnostic value of circRNA. Statistically, P < 0.05 was considered to be significantly different. Fluorescence quantitative PCR results showed that compared with patients with AIS-LVO who underwent concurrent endovascular treatment and had a good prognosis, the expression level of hsa_circ_0045128 in patients with poor prognosis was significantly upregulated, see Figure 2 .

[0054] Through ROC curve analysis and AUC calculation, it was found that the AUC of hsa_circ_0045128 was 0.848, with a 95% confidence interval of 0.754-0.941, corresponding to a sensitivity of 82.14% and a specificity of 76.92% (see Figure 3 These results suggest that hsa_circ_0045128 can serve as an important biomarker for predicting the prognosis of endovascular treatment in patients with AIS-LVO.

Claims

1. A molecular biomarker to predict the prognosis of endovascular treatment of AIS-LVO, It is characterized in that The molecular biomarker is hsa_circ_0045128, and its nucleotide sequence is shown in SEQ ID NO.

1.

2. Application of hsa_circ_0045128 as a marker in the preparation of detection reagents for predicting the prognosis of intravascular treatment of AIS-LVO.

3. A test reagent for predicting the prognosis of intravascular treatment of AIS-LVO, It is characterized in that Includes reagents for detecting hsa_circ_0045128.

4. A detection reagent for predicting the prognosis of intravascular treatment of AIS-LVO according to claim 3, It is characterized in that The reagents for detecting hsa_circ_0045128 include primers shown in SEQ ID NO.2 and SEQ ID NO.3, and primers for internal reference genes.

5. A detection reagent for predicting the prognosis of intravascular treatment of AIS-LVO according to claim 4, It is characterized in that The internal reference gene is GAPDH, and the primer sequences of the internal reference gene are shown in SEQ ID NO.4 and SEQ ID NO.

5.

6. A detection kit for predicting the prognosis of intravascular treatment of AIS-LVO, It is characterized in that The invention comprises the detection reagent as claimed in claim 3.

Citation Information

Patent Citations

  • Application of hsacirc0007364 as marker for diagnosing cerebral apoplexy obliterans

    CN117363714A

  • Circular rnas for the diagnosis and treatment of brain disorders

    US20210079474A1